SAS Announces License of Exclusive rights for Diacomit® (Stiripentol) with taiba Middle East FZ LLC in Saudi Arabia, United Arab Emirates, Bahrain, Kuwait, Oman & Qatar 29 July 2025 Biocodex SAS Announces License of Exclusive rights for Diacomit® (Stiripentol) with taiba Middle East FZ LLC in Saudi Arabia, United Arab Emirates, Bahrain, Kuwait, Oman & Qatar July 1st, 2025 — Biocodex and taiba Middle East FZ LLC have signed an exclusive licensing agreement for the Saudi Arabia, United Arab Emirates, Bahrain, Kuwait, Oman & Qatar markets for Diacomit® (stiripentol). Diacomit® is an antiepileptic drug approved for adjunctive treatment in Dravet syndrome also known as severe myoclonic epilepsy in infancy (SMEI). Dravet syndrome is a severe infantile-onset and highly treatment-resistant epileptic encephalopathy that is thought to affect approximately 1 in 20,000 ...

Biocodex SAS Announces License of Exclusive rights for Diacomit® (Stiripentol) with taiba Middle East FZ LLC in Saudi Arabia, United Arab Emirates, Bahrain, Kuwait, Oman & Qatar 29 July 2025 Article Read the article here FR Read the article here ENG July 1 st , 2025 — Biocodex and taiba Middle East FZ LLC have signed an exclusive licensing agreement for the Saudi Arabia, United Arab Emirates, Bahrain, Kuwait, Oman & Qatar markets for Diacomit® (stiripentol). Diacomit® is an antiepileptic drug approved for adjunctive treatment in Dravet syndrome also known as severe myoclonic epilepsy in infancy (SMEI). Dravet syndrome is a severe infantile-onset and highly treatment-resistant epileptic encephalopathy that is thought to affect approximately 1 in 20,000 individuals. “We are pleased to have entered into this collaboration with taiba Middle East FZ LLC which is a step forward to Diacomit development in Middle East. We remain committed to bringing a new treatment option to Dravet patients and address unmet needs of these patients suffering from one of the most resistant forms of early onset epilepsy” says Caroline Schreiner, Chief Business Officer Orphan Disease Division of Biocodex. “We are honored to collaborate with Biocodex in bringing Diacomit® to patients living with Dravet syndrome across the Middle East. This partnership reinforces our commitment to addressing the region’s most pressing healthcare challenges. Diacomit® is a valuable addition to our growing portfolio of innovative therapies focused on patients with the greatest unmet medical needs”. Says Saif Al Hasani, Chief Executive Officer of taiba healthcare. About Diacomit ® (stiripentol) Diacomit® is an antiseizure medication developed by Laboratories Biocodex. Diacomit® is approved for adjunctive treatment with clobazam and valproate in Dravet syndrome in 27 countries in the EU (2007), Canada (2012), Japan (2012), USA (2018), Australia (2019), Argentina (2020), Taiwan (2021), South Africa (2022), Peru (2025) About Biocodex Biocodex is an independent multinational pharmaceutical company founded in France in 1953. It is headquartered in Gentilly (France) with its American subsidiary in San Mateo (CA). The company is focused on discovering, developing and commercializing innovative therapeutics relating to the central nervous system (epilepsy, pain management, psychiatry), gastroenterology (microbiota) and women health. For any information please contact: Hubert Chapellier, Head of Partnership, Biocodex T: +33 (0)1 41 24 46 69 [email protected] About taiba Middle East FZ LLC Established in 1980, taiba healthcare is a regional leader in delivering innovative treatments for patients with orphan and rare diseases. Through strategic marketing, sales, and distribution, taiba connects healthcare systems across the MENA region with breakthrough therapies—via early access programs and commercialization. Driven by a clear mission to close the treatment gap, taiba empowers medical institutions with cutting-edge solutions and exceptional service. Over four decades of collaboration with clinicians, hospitals, and global partners have earned the company a trusted reputation in rare disease care, always putting patients at the center of progress. For more information, please contact: Dilara Kutuk PR & public communication T: +96824442222 [email protected]

The release as fetched from its publisher. biocodex.com ↗